ANGO ANGIODYNAMICS INC

BULLISH Impact: 8/10 8-K
Horizon immediate Filed Apr 2, 2026 Processed 2mo ago SEC 0001140361-26-012891
8-K Item 2.02: Earnings release
Latest settled — T+20d
ANGO ▲ +6.11% at T+20d
LONG call ✓ call won +6.11% · α vs SPY -3.77% · entry $10.31 → $10.94
Next anchor: T+60d in 20d
Last close $11.93 (close Jun 8) · +15.71% from $10.31 entry
Entry anchored
Apr 1, 03:59 PM ET
via Databento tick
T+1d
-4.56%
call -4.56% · α -5.03%
$9.84
settled 2mo ago
T+5d
-4.95%
call -4.95% · α -8.57%
$9.80
settled 2mo ago
T+20d
+6.11%
call +6.11% · α -3.77%
$10.94
settled 6w ago
T+60d
—
call — · α —
—
in 20d

Price Chart

Loading chart...

Executive Summary

AngioDynamics reported strong fiscal Q3 2026 results with 8.9% YoY revenue growth and a 19% increase in Med Tech sales, driven by Auryon and NanoKnife. The company raised full-year guidance for net sales and Adjusted EBITDA for the third consecutive quarter, signaling sustained profitable growth despite a slight YoY decline in gross margin due to tariffs. CEO Jim Clemmer will retire during fiscal 2027 upon the appointment of a successor.

Key Financial Metrics

Guidance
$313.5 - $315.5 M
raised
Gross Margin
52.9%

Actionable Insight

The stock is likely to react positively to the strong Med Tech growth and raised guidance, which indicates the company's strategic transformation is gaining traction. However, traders should monitor the impact of tariffs on gross margins and the leadership transition, as the CEO retirement could introduce near-term uncertainty despite the strong operational performance.

Key Facts

  • Q3 revenue of $78.4M, up 8.9% YoY (consensus: $76.8M), beating by 2.1%
  • Med Tech sales grew 19.0% YoY to $37.3M, sixth consecutive quarter of double-digit growth
  • Adjusted EBITDA of $1.8M, up from $1.3M in prior year quarter
  • Full-year 2026 guidance raised: Net sales to $313.5-$315.5M (up from $312-$314M), Adjusted EBITDA to $10.0-$12.0M (up from $8.0-$10.0M)
  • Gross margin was 52.9%, down 110 bps YoY due to tariffs and inflation
  • CEO Jim Clemmer to retire in fiscal 2027; board has initiated a search for successor

Financial Impact

$78.4M revenue (8.9% YoY growth), $37.3M Med Tech sales (19% YoY growth), raised full-year guidance

revenueepsebitdaguidance

Risk Factors

  • Gross margin declined 110 bps YoY to 52.9% due to tariffs and inflation, which could pressure profitability if sustained
  • CEO Jim Clemmer's planned retirement in fiscal 2027 introduces leadership transition risk, which could affect strategic continuity

Market Snapshot

Exchange
Nasdaq
Sector
Surgical & Medical Instruments & Apparatus

Documents Analyzed

This report is based on 7 SEC documents filed with EDGAR.

DocumentAccession Number
8-K Filing (Primary)0001140361-26-012891
Document: ef20069681_8k.htm0001140361-26-012891
Document: ef20069681_ex99-2.htm0001140361-26-012891
Document: 0001140361-26-012891-index-headers.html0001140361-26-012891
Document: 0001140361-26-012891-index.html0001140361-26-012891
Document: 0001140361-26-012891.txt0001140361-26-012891
8-K Data (Synthetic)0001140361-26-012891

US Market Status

Market Closed — Opens in 7h 2m

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access